Provided by Tiger Trade Technology Pte. Ltd.

Instil Bio, Inc.

7.58
+0.15002.02%
Post-market: 7.580.00000.00%19:30 EDT
Volume:9K
Turnover:69.79K
Market Cap:51.41M
PE:-1.70
High:7.88
Open:7.40
Low:7.40
Close:7.43
52wk High:33.83
52wk Low:5.67
Shares:6.78M
Float Shares:3.62M
Volume Ratio:1.66
T/O Rate:0.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4688
EPS(LYR):-10.7032
ROE:-25.33%
ROA:-10.77%
PB:0.48
PE(LYR):-0.71

Loading ...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Yesterday

TIL Enviro Sets Board Meeting to Approve Interim Results and Consider Dividend

TIPRANKS
·
Aug 17

Instil Bio, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Instil Bio Q2 Adj. EPS $(0.45) Misses $(0.43) Estimate

Benzinga Earnings
·
Aug 14

Instil Bio Q2 FY26 Net Loss Per Share Narrows to $0.63 from Year-Ago $3.24

Reuters
·
Aug 14

Instil Bio Q2 Basic EPS USD -0.63

THOMSON REUTERS
·
Aug 14

Instil Bio Q2 Operating Expenses USD 5.581 Million

THOMSON REUTERS
·
Aug 14

Press Release: Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
Aug 14

TIL Limited Clears Q1 FY2026 Results and Shifts Registrar for Share Services

TIPRANKS
·
Aug 13

Hutchison Ports, TIL Withdraw Barcelona Terminal Deal from EU Merger Review

Dow Jones
·
Aug 10

Instil Bio, Inc. Expected to Post a Loss of 43 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Iovance Expands Solid Tumor Pipeline With New IOV-5001 TIL Trial

TIPRANKS
·
Aug 07

Press Release: Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million

Dow Jones
·
Aug 03

Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026

GlobeNewswire
·
Jul 30

TIL Enviro Wins Unanimous Shareholder Backing at 2026 AGM

TIPRANKS
·
Jun 23

Instil Bio Shareholders Back Directors and Auditor at Meeting

TIPRANKS
·
Jun 12

Instil Bio shareholders ratify RSM US LLP as auditor for 2026

Reuters
·
Jun 12

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

GlobeNewswire
·
Jun 04

TIL Enviro Sets 2026 AGM to Approve Results, Board Changes and Share Issue Mandate

TIPRANKS
·
May 29

Allogene names Zachary Roberts CEO, succeeding David Chang effective July 1, 2026

Reuters
·
May 29